Cargando…

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19

BACKGROUND: Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS: sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnaldos-Carrillo, María, Noguera-Velasco, José Antonio, Martínez-Ardil, Isabel M., Riquelme-Pérez, Alejandro, Cebreiros-López, Iria, Hernández-Vicente, Álvaro, Ros-Lucas, José Antonio, Khan, Amjad, Bayes-Genís, Antoni, Pascual-Figal, Domingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086099/
https://www.ncbi.nlm.nih.gov/pubmed/37137804
http://dx.doi.org/10.1016/j.medcli.2023.04.005
_version_ 1785022072990203904
author Arnaldos-Carrillo, María
Noguera-Velasco, José Antonio
Martínez-Ardil, Isabel M.
Riquelme-Pérez, Alejandro
Cebreiros-López, Iria
Hernández-Vicente, Álvaro
Ros-Lucas, José Antonio
Khan, Amjad
Bayes-Genís, Antoni
Pascual-Figal, Domingo
author_facet Arnaldos-Carrillo, María
Noguera-Velasco, José Antonio
Martínez-Ardil, Isabel M.
Riquelme-Pérez, Alejandro
Cebreiros-López, Iria
Hernández-Vicente, Álvaro
Ros-Lucas, José Antonio
Khan, Amjad
Bayes-Genís, Antoni
Pascual-Figal, Domingo
author_sort Arnaldos-Carrillo, María
collection PubMed
description BACKGROUND: Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS: sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. RESULTS: 495 patients were studied (53% male, age: 57.6 ± 17.6). At admission, median sST2 concentrations was 48.5 ng/mL [IQR, 30.6–83.1 ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n = 45, 9.1%) (45.6 [28.0, 75.9] ng/mL vs. 144 [82.6, 319] ng/mL, p < 0.001) and those admitted to ICU (n = 46, 9.3%) (44.7 [27.5, 71.3] ng/mL vs. 125 [69.0, 262] ng/mL, p < 0.001). sST2 levels > 210 ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3–97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. CONCLUSIONS: sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies.
format Online
Article
Text
id pubmed-10086099
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-100860992023-04-11 Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19 Arnaldos-Carrillo, María Noguera-Velasco, José Antonio Martínez-Ardil, Isabel M. Riquelme-Pérez, Alejandro Cebreiros-López, Iria Hernández-Vicente, Álvaro Ros-Lucas, José Antonio Khan, Amjad Bayes-Genís, Antoni Pascual-Figal, Domingo Med Clin (Barc) Original Article BACKGROUND: Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS: sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. RESULTS: 495 patients were studied (53% male, age: 57.6 ± 17.6). At admission, median sST2 concentrations was 48.5 ng/mL [IQR, 30.6–83.1 ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n = 45, 9.1%) (45.6 [28.0, 75.9] ng/mL vs. 144 [82.6, 319] ng/mL, p < 0.001) and those admitted to ICU (n = 46, 9.3%) (44.7 [27.5, 71.3] ng/mL vs. 125 [69.0, 262] ng/mL, p < 0.001). sST2 levels > 210 ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3–97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. CONCLUSIONS: sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies. Elsevier España, S.L.U. 2023-04-11 /pmc/articles/PMC10086099/ /pubmed/37137804 http://dx.doi.org/10.1016/j.medcli.2023.04.005 Text en © 2023 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Arnaldos-Carrillo, María
Noguera-Velasco, José Antonio
Martínez-Ardil, Isabel M.
Riquelme-Pérez, Alejandro
Cebreiros-López, Iria
Hernández-Vicente, Álvaro
Ros-Lucas, José Antonio
Khan, Amjad
Bayes-Genís, Antoni
Pascual-Figal, Domingo
Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title_full Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title_fullStr Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title_full_unstemmed Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title_short Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
title_sort value of increased soluble suppressor tumorigenicity biomarker 2 (sst2) on admission as an indicator of severity in patients with covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086099/
https://www.ncbi.nlm.nih.gov/pubmed/37137804
http://dx.doi.org/10.1016/j.medcli.2023.04.005
work_keys_str_mv AT arnaldoscarrillomaria valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT nogueravelascojoseantonio valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT martinezardilisabelm valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT riquelmeperezalejandro valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT cebreiroslopeziria valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT hernandezvicentealvaro valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT roslucasjoseantonio valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT khanamjad valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT bayesgenisantoni valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19
AT pascualfigaldomingo valueofincreasedsolublesuppressortumorigenicitybiomarker2sst2onadmissionasanindicatorofseverityinpatientswithcovid19